World Pharma Today is a leading Magazine featuring latest industry developments for the Pharmaceutical C-level executives.
Pharmanovia CEO, James Burt appointed Chair of Medicines for Europe’s Value Added Medicines (VAM) sector group PRESS RELEASE (business and pharma trade only) FOR IMMEDIATE RELEASE, Basildon, 9 November 2023 Pharmanovia, a... More information ...
Today advances in pharma analytical Trends and technologies... Rose Nor Apr 6, 2022 0 179 News and Trends All Industrial Player Section Public Health Matter Section Bharat Biotech seeks DCGI nod for phase 2/3 Covaxin booster... Rose Nor May 4, 2022 0 129 GSK launches once daily, ...
Established in 2006,CordenPharmatoday employs more than 2,600 people in 11 manufacturing facilities and one R&D laboratory located across Europe and the US. CordenPharma achieved a turnover of more than 750 million euros in 2021. Read... South Africa's Aspen COVID-19 vaccine plant risks closu...
Trusted commercial intelligence, consensus forecasts, Vantage news and analysis for pharma, biotech and medtech industry - Explore Evaluate
PharmAnt is the updated and trusted news hub of the pharmaceutical sector, rare disorders, new technologies, recent Oncology therapies' approvals and, more.
Catalyst Pharma stock news, updates & related news. Find out why Catalyst Pharma's (CPRX) news sentiment is more negative in relation to stocks in the Healthcare sector.
As 2024 comes to a close, MobiHealthNews asked executives from across the digital health sector about their biggest surprises and most noteworthy events from the year. The execs highlight AI's potential, oncology imaging breakthroughs, nutrition's role in healthcare, inflated AI valuations, cyber...
Let’s break it down further: First up, we start by looking at the capitalmarket. Over the past decade, China'sinnovativedrug sector has attracted more than 1 trillion RMB in funding. For a strategic emerging industry like this, that kind of cash is like rocket fuel for innovation. ...
While Merck ($63.9B) and Pfizer ($62.5B) hold the top spots, double-digit growth from AstraZeneca (~18%), Eli Lilly (~34%), Novo Nordisk (~26%), and Amgen (~18%) signals an accelerating transformation in the sector’s competitive landscape. The continued strength of the GLP-1 ...